We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-17.92%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$999M
AUM Growth
-$111M
Cap. Flow
+$145M
Cap. Flow %
14.51%
Top 10 Hldgs %
53.54%
Holding
68
New
18
Increased
13
Reduced
17
Closed
15
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
1.3 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
1.4 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$73.3M
2
XNCR icon
Xencor
XNCR
+$36.3M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$33.3M
4
SLDB icon
Solid Biosciences
SLDB
+$27.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$25.8M

Top Sells

Rank Stock Value
1
MGNX icon
MacroGenics
MGNX
+$31.8M
2
ASND icon
Ascendis Pharma A/S
ASND
+$25.6M
3
KYNB icon
Kyntra Bio
KYNB
+$22.2M
4
SRRK icon
Scholar Rock
SRRK
+$20.2M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.99%
2 Miscellaneous 13.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AFMD icon
51
DELISTED
Affimed
AFMD
$492K 0.05%
+15,822
New +$588K
2018 Q4
0 quarters
CNST
52
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$318K 0.03%
79,194
-200,806
-72% -$1.21M
2018 Q3
1 quarter
PRQR icon
53
ProQR Therapeutics
PRQR
$189M
$174K 0.02%
+11,022
New +$202K
2018 Q4
0 quarters
ASMB icon
54
CALL
Assembly Biosciences
ASMB
$412M
– –
-12,342
Closed -$5.5M –
ELAN icon
55
Elanco Animal Health
ELAN
$11.8B
– –
-190,000
Closed -$6.63M –
MGNX icon
56
MacroGenics
MGNX
$208M
– –
-1,481,086
Closed -$31.8M –
MRSN icon
57
DELISTED
Mersana Therapeutics
MRSN
– –
-19,825
Closed -$4.96M –
RARE icon
58
CALL
Ultragenyx Pharmaceutical
RARE
$1.44B
– –
-325,000
Closed -$24.8M –
RARE icon
59
Ultragenyx Pharmaceutical
RARE
$1.44B
– –
-254,000
Closed -$19.4M –
SPRO icon
60
Spero Therapeutics
SPRO
$64.1M
– –
-892,741
Closed -$9.38M –
TECX icon
61
Tectonic Therapeutic
TECX
$411M
– –
-5,721
Closed -$3.56M –
PHXM
62
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
– –
-6,957
Closed -$590K –
INFI
63
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-462,068
Closed -$1.25M –
APTX
64
DELISTED
Aptinyx Inc. Common Stock
APTX
– –
-41,037
Closed -$1.19M –
JNCE
65
CALL
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-497,400
Closed -$3.23M –
KDMN
66
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-1,480,870
Closed -$4.95M –
FTSV
67
DELISTED
Forty Seven, Inc. Common Stock
FTSV
– –
-99,000
Closed -$1.48M –
ACHN
68
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-1,564,080
Closed -$5.76M –
1 2
3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2018 Portfolio in Review

As of Q4 2018, EcoR1 Capital held 68 positions worth $999M, down 10% from $1.11B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

EcoR1 Capital deployed $145M of net new capital in Q4 2018, opening 18 new positions and adding to 13 existing holdings. Its largest new stake was argenx: 825,087 shares worth $79.3M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 87% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $25.6M trimmed.

  • EcoR1 Capital's largest Q4 2018 buy was argenx: 825,087 shares worth $79.3M.
  • EcoR1 Capital added most to Ionis Pharmaceuticals in Q4 2018, an estimated $33.3M increase.
  • EcoR1 Capital's biggest Q4 2018 reduction was Ascendis Pharma A/S, cutting an estimated $25.6M.
  • EcoR1 Capital fully exited MacroGenics in Q4 2018, selling an estimated $31.8M.
  • EcoR1 Capital's ten largest holdings make up 54% of its $999M portfolio in Q4 2018.
  • EcoR1 Capital opened 18 new positions and closed 15 in Q4 2018.
  • EcoR1 Capital's portfolio value fell 10% quarter-over-quarter to $999M.

Based on EcoR1 Capital's 13F filing for Q4 2018, filed 14 Feb 2019.